Your browser is no longer supported. Please, upgrade your browser.
PSNL Personalis, Inc. daily Stock Chart
Personalis, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own2.30% Shs Outstand31.13M Perf Week8.87%
Market Cap221.67M Forward P/E- EPS next Y-0.90 Insider Trans-12.58% Shs Float30.51M Perf Month-17.50%
Income-22.00M PEG- EPS next Q-0.25 Inst Own81.40% Short Float4.76% Perf Quarter-26.37%
Sales60.20M P/S3.68 EPS this Y15.70% Inst Trans6.46% Short Ratio3.05 Perf Half Y-54.15%
Book/sh3.58 P/B1.99 EPS next Y10.90% ROA- Target Price19.50 Perf Year-
Cash/sh4.09 P/C1.74 EPS next 5Y12.40% ROE- 52W Range4.27 - 31.88 Perf YTD-34.68%
Dividend- P/FCF- EPS past 5Y- ROI18.30% 52W High-77.67% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin33.80% 52W Low66.74% ATR0.90
Employees147 Current Ratio3.00 Sales Q/Q47.00% Oper. Margin-33.20% RSI (14)46.77 Volatility11.28% 14.36%
OptionableYes Debt/Eq0.00 EPS Q/Q-73.10% Profit Margin-36.50% Rel Volume1.44 Prev Close7.65
ShortableYes LT Debt/Eq0.00 EarningsMar 25 AMC Payout- Avg Volume476.87K Price7.12
Recom1.50 SMA204.34% SMA50-21.95% SMA200-47.43% Volume688,805 Change-6.93%
Sep-26-19Upgrade BofA/Merrill Neutral → Buy $22
Jul-15-19Initiated Oppenheimer Outperform $29
Jul-15-19Initiated Morgan Stanley Overweight $28
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated BofA/Merrill Neutral $27
Mar-25-20 04:01PM  Personalis Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire +7.53%
03:00PM  Personalis Inc to Host Earnings Call ACCESSWIRE
Mar-11-20 04:05PM  Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 Business Wire -11.60%
Feb-26-20 08:00AM  Personalis, Inc. to Present at Immuno-Oncology 360 Conference Business Wire
Feb-18-20 04:05PM  Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference Business Wire
08:00AM  Personalis to Participate at the Cowen 40th Annual Health Care Conference Business Wire
Feb-11-20 01:00PM  Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program Business Wire
08:00AM  Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program GlobeNewswire
Jan-22-20 12:15PM  Personalis, Inc. to Present at Precision Medicine World Conference 2020 Business Wire +5.79%
Jan-07-20 05:15PM  Personalis, Inc. Announces the Launch of the NeXT Dx Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment Business Wire +5.41%
07:30AM  [video]This Sleeper Name Could Wake Up in 2020
Dec-26-19 10:48AM  These new Bay Area stocks from 2019 are 'underwater' as year ends American City Business Journals
Dec-19-19 06:28PM  Hedge Funds Are Dumping Personalis, Inc. (PSNL) Insider Monkey
Dec-17-19 08:00AM  3 Strong Buy Healthcare Stocks That Can Double in 2020 TipRanks +6.54%
Dec-10-19 08:00PM  Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019 Business Wire +6.48%
Nov-21-19 08:00AM  Personalis, Inc. to Present at NeoAg Summit US 2019 Business Wire
Nov-19-19 04:05PM  Personalis to Present at Upcoming Investor Conferences Business Wire
08:00AM  Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies Business Wire
Nov-17-19 04:30PM  Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference Business Wire
Nov-13-19 04:05PM  Personalis Reports Third Quarter 2019 Financial Results Business Wire +6.97%
Nov-12-19 05:30PM  Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services Business Wire
Nov-06-19 01:15PM  Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting Business Wire
Nov-01-19 11:03AM  Here is What Hedge Funds Think About Personalis, Inc. (PSNL) Insider Monkey
Oct-30-19 04:05PM  Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019 Business Wire
Oct-24-19 11:00AM  Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 Business Wire
Oct-08-19 11:00AM  Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019 Business Wire -7.57%
Sep-26-19 04:05PM  Personalis Receives New Order from the VAs Million Veteran Program Total Awarded to Date Now $145M Business Wire -5.36%
Sep-20-19 01:11PM  What Kind Of Shareholder Owns Most Personalis, Inc. (NASDAQ:PSNL) Stock? Simply Wall St.
Sep-12-19 04:07PM  Personalis Appoints Karin Eastham to Its Board of Directors Business Wire
Sep-09-19 08:00AM  Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial Business Wire -11.46%
Aug-26-19 04:32PM  Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-13-19 04:02PM  Personalis Reports Second Quarter 2019 Financial Results Business Wire
Aug-07-19 08:00AM  Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study Business Wire +10.97%
Aug-01-19 04:05PM  Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications Business Wire -11.28%
Jul-30-19 08:00AM  Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019 Business Wire
Jul-18-19 11:20AM  2 Small-Cap Biotech IPOs You Should Know About Motley Fool +5.37%
Jul-06-19 11:11AM  3 Top Stocks That Aren't On Wall Street's Radar Motley Fool
Jun-24-19 04:05PM  Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option Business Wire
Jun-20-19 07:42AM  Personalis IPO: What You Need To Know Benzinga
Jun-19-19 09:10PM  Personalis Prices Initial Public Offering of Common Stock Business Wire
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen RichardChief Scientific OfficerMar 27Option Exercise0.0015,0000121,500Mar 27 07:59 PM
Chen RichardChief Scientific OfficerMar 25Option Exercise0.0010,0000106,500Mar 27 07:59 PM
Chen RichardChief Scientific OfficerMar 09Option Exercise0.001,000060,000Mar 11 05:37 PM
Chen RichardChief Scientific OfficerMar 09Sale7.841,0007,84059,000Mar 11 05:37 PM
Chen RichardChief Scientific OfficerMar 02Option Exercise0.001,000060,000Mar 04 06:05 PM
Chen RichardChief Scientific OfficerMar 02Sale8.761,0008,76059,000Mar 04 06:05 PM
Chen RichardChief Scientific OfficerFeb 25Option Exercise0.00101,0000160,000Feb 27 09:40 PM
Chen RichardChief Scientific OfficerFeb 25Sale8.77101,000885,77059,000Feb 27 09:40 PM
LUDLUM KENDirectorFeb 07Option Exercise3.804,16715,83550,000Feb 11 06:44 PM
Chen RichardChief Scientific OfficerJan 07Option Exercise0.4412,0005,28059,000Jan 09 07:57 PM
Chen RichardChief Scientific OfficerDec 20Option Exercise0.4412,0005,28047,000Dec 26 06:54 PM